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Abstract
Organophosphorus nerve agent (OPNA) adducts to butyrylcholinesterase (BChE) can be used to 
confirm exposure in humans. A highly accurate method to detect G-series and V-series OPNA 
adducts to BChE in 75 μL of filtered blood, serum, or plasma has been developed using 
immunomagnetic separation (IMS) coupled with liquid chromatography tandem mass 
spectrometry (LC-MS/MS). The reported IMS method captures > 88% of the BChE in a specimen 
and corrects for matrix effects on peptide calibrators. The optimized method has been used to 
quantify baseline BChE levels (unadducted and OPNA-adducted) in a matched set of serum, 
plasma and whole blood (later processed in-house for plasma content) from 192 unexposed 
individuals to determine the interchangeability of the tested matrices. The results of these 
measurements demonstrate the ability to accurately measure BChE regardless of the format of the 
blood specimen received. Criteria for accepting or denying specimens were established through a 
series of sample stability and processing experiments. The results of these efforts are an optimized 
and rugged method that is transferrable to other laboratories and an increased understanding of the 
BChE biomarker in matrix.
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Introduction
The threat of toxic organophosphorus nerve agent (OPNA) use has led to the development of 
bioanalytical methods to detect G-series and V-series OPNA exposure in humans. The 
Chemical Weapons Convention, administered by the Organisation for the Prohibition of 
Chemical Weapons, classifies OPNA compounds as Schedule 1 chemical warfare agents 
since they are solely used as chemical weapons [1]. Organophosphorus (OP) compounds, 
including nerve agents and pesticides, inhibit cholinesterases (ChE) by phosphorylating 
serine in the enzymatic active site resulting in over-stimulation of cholinergic receptors [2]. 
ChE inhibition causes symptoms ranging from muscle twitching and seizures to death in 
high level exposures [3, 4]. OP agents, specifically sarin (GB), were used as weapons in the 
Matsumoto City and Tokyo subway attacks [4], the Iraq-Iran conflict [5] and most recently 
in Syria [6]. Hence, reliable methods for immediate and retrospective detection of OPNA 
exposure are essential.
Historically, the Ellman assay has been the primary method to diagnose OP exposure in 
clinical samples. The Ellman assay measures erythrocyte acetylcholinesterase (AChE) 
activity using a kinetic colorimetric system [7] and has been adapted to measure 
butyrylcholinesterase (BChE) [8]. Despite its advantages, the Ellman assay is unable to 
identify specific OP compounds, is unreliable at inhibition levels <20%, and is unsuitable for 
retrospective detection due to normal restoration of enzyme activity [9, 10].
Other approaches for detecting OPNA exposure include the measurement of OPNA 
hydrolysis products in urine [12], OPNA fluoride reactivation in blood [11] and OPNA 
adduction to albumin in blood [18]. OPNA metabolites including GB, soman, cyclosarin, 
VX and Russian-VX phosphonic acids are rapidly detected in urine using liquid 
chromatography tandem mass spectrometry (LC-MS/MS) [12, 13]. A significant limitation 
of the method is that > 90% of these hydrolysis products are eliminated in vivo within 2–3 
days after exposure [14]. Fluoride reactivation can detect low level nerve agent exposure up 
to 35 days post OP exposure [15]. The limitations of fluoride reactivation include its 
inability to measure endogenous BChE levels or aged OPNA adducts, and spontaneous 
reactivation and denaturation of the enzyme which affect quantitative measurements [16]. 
Albumin is a common protein biomarker since nerve agents covalently bind to tyrosine-411 
of albumin. Unlike other protein biomarkers, tyrosine-411 of albumin does not ‘age’ or 
degrade in the presence of oximes [17]. Furthermore, albumin is the most abundant protein 
in blood plasma (40 mg/mL) and has a relatively long half-life of 20 days [18,19]. However, 
albumin reacts 500 times slower with nerve agents in blood than cholinesterases [19].
BChE is a prominent OPNA target [18, 20]. BChE acts as a natural scavenger of OPNA 
[21], is easily extracted from blood plasma, has a high rate of reaction [22], and is vastly 
more abundant in serum than AChE [20]. BChE adducts are detectable up to 16 days post-
exposure making them an effective biomarker for retrospective detection [23].
The BChE diagnostic method and immunomagnetic separation (IMS) coupled with isotope 
dilution LC-MS/MS method was originally developed by The Netherlands Organisation for 
Applied Scientific Research (TNO) and Knaack et al. [16, 24]. In brief, BChE is extracted 
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from the specimen using anti-BChE antibody (Ab) conjugated to ferromagnetic Protein G 
beads. Upon extraction, BChE is digested using pepsin and analyzed by LC-MS/MS (Fig. 
1). MS analysis readily reveals whether a nine amino acid peptide formed by pepsin 
digestion, FGES198AGAAS (where S198 is the active site serine), contains the OP adduct to 
the serine-198 residue [16, 24].
The reported method has been modified significantly to enhance accuracy and to expand our 
knowledge of BChE in matrix. To optimize the IMS-LC-MS/MS method, GB and VX 
peptides were used as model analytes to represent G-series and V-series OPNAs, 
respectively. V-series agents signify long persistence, unlike G-series which are non-
persistent. The new method quantifies unadducted BChE, GB-adducted BChE (GB-BChE) 
and VX-adducted BChE (VX-BChE) in human serum and plasma samples. Endogenous 
BChE protein levels were measured in a matched-set of 192 individual unexposed serum, 
plasma, and plasma harvested from whole blood samples. BChE sample handling and 
stability experiments were conducted. The result of these efforts is a highly accurate and 
rugged method for detection of OPNA exposure in humans.
Materials and Methods
Reagents and Materials
Material sources were as follows: anti-butyrylcholinesterase monoclonal antibody from 
clone 3E8, KingFisher deep 96-well plates, KingFisher shallow 96-well plates and Easy 
Pierce Heat Sealing foil (Fisher Scientific); pepsin from porcine gastric mucosa, PBS with 
Tween-20, formic acid (~98% purity) (Sigma-Aldrich Chemical Company); HPLC-grade 
water and acetonitrile (Tedia); MultiScreen 96-well 0.45 μm PVDF plates (EMD Millipore); 
96-well PCR plates, adhesive PCR foil (Eppendorf); protein precipitation plates (Pierce, 
Rockford, IL); Dynabeads Protein G (Invitrogen); Aquasil C18 HPLC column (1.0 × 50 
mm, 3 μm) (Thermo Scientific). Native and labeled synthetic peptides (>58% peptide 
content) were synthesized at TNO. Pooled serum for quality controls (QC) was purchased 
from Bioreclamation and spiked with solvent, GB or VX agent at Battelle Memorial 
Institute.
Convenience Sample Set
A convenience set containing matched-set serum, plasma and whole blood specimens from 
192 healthy individuals with no known exposure to nerve agents was purchased from 
Tennessee Blood Services. Only donor age, sex, and smoking status were provided; 
therefore, no institutional review board approval was required. Baseline BChE protein levels 
and protein stability was assessed among the three matrices using the reported IMS-LC-
MS/MS method. BChE protein stability experiments were conducted over 2 weeks using 
pooled convenience set samples stored between 37°C to −70°C.
Synthetic Calibrators and Quality Controls
The peptide calibration curve was comprised of a mixture of native unadducted BChE 
[FGESAGAAS], GB-BChE [FGES(-GB)AGAAS] and VX-BChE [FGES(-VX)AGAAS] 
synthetic peptides. The calibration curve was comprised of 8 calibrators at 1, 4, 6, 16, 32, 
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63, 125, and 250 ng/mL in 0.6% formic acid in HPLC-grade water. The calibration range 
corresponded with the range of BChE concentrations observed from the convenience set 
(13.8–58.3 ng/mL). The lowest point on the calibration curve is the lowest reportable limit 
(LRL) for GB-BChE and VX-BChE, while BChE had a LRL of 4 ng/mL. The highest point 
on the calibration curve is above the range of expected results. The internal calibrator was 
comprised of a mixture containing 13C9-isotopically labeled BChE, GB-BChE and VX-
BChE synthetic peptides in 0.6% formic acid in HPLC-grade water. No isotopic 
contributions between the labeled and native peptides were observed. Peptide content was 
measured in triplicate by MidWest Biotech using amino acid analysis to provide accurate 
calibrator and internal standard concentrations.
Quality control materials included three QC high (QCH), one QC low (QCL) and one matrix 
blank serum sample. The QCH samples were 100% unadducted BChE (QCH BChE); 100% 
GB-adducted BChE (QCH GB); and 100% VX-adducted BChE (QCH VX). The QCL 
material was prepared as a single mixture comprised of 5 parts QCH BChE, 2 parts QCH 
GB and 1 part QCH VX. A small excess of unadducted VX in the QCH VX serum requires 
additional QCH BChE serum to scavenge the free VX when preparing the QCL mixture. 
The matrix blank QC material was prepared from 100% GA-adducted BChE (Battelle) since 
GA is not a current analyte in the method due to the unavailability of appropriate synthetic 
peptide calibrators.
Preparation of Specimens
At least one day prior to sample processing, anti-BChE Ab was conjugated to the magnetic 
Protein G Dynabeads as described by Knaack et al. [24]. Once a stock of anti-BChE beads 
were prepared, a 125 μL aliquot of the five QCs and specimens were filtered through a 96-
well 0.45 μm filter plate at 3,000 ×g at 20°C to remove particulates. Whole blood samples 
(including the convenience set) were centrifuged at 3,000 ×g at 20°C to harvest plasma. 
Unfiltered blood was not processed through the method since the quantitative values for the 
unfiltered blood were greater than ± 20% of the theoretical. A 75 μL aliquot of the filtered 
specimen was transferred to a deep 96-well plate (sample plate). To address matrix effects, 
75 μL of filtered matrix blank QC material was added to wells that would later receive the 
calibration curve. In a separate shallow 96-well plate, 50 μL of anti-BChE beads were added 
to the same number of wells as samples to be measured.
Sample Processing
Using a KingFisher Flex Magnetic Particle Processor (Thermo Scientific), the anti-BChE 
beads were transferred to the specimens in the sample plate. The sample plate was covered 
with adhesive foil, placed on the Eppendorf MixMate and shaken at 1,400 rpm for 2 hours at 
room temperature. During the sample plate incubation, the following were prepared: pepsin 
solution, three wash plates and the digestion plate. The 2 mg/mL pepsin solution in 0.6% 
formic acid in HPLC-grade water was made at least 30 min prior to use. Wash plates were 
made by adding 500 μL of PBS with Tween-20 to each well of three deep 96-well plates. 
The digestion plate was prepared by adding 10 μL internal calibrator to each well of a 
shallow 96-well plate. Each calibrator (75 μL of 1, 4, 6, 16, 32, 63, 125 and 250 ng/mL 
native BChE, GB-BChE and VX-BChE peptides) was added to the appropriate wells on the 
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digestion plate. The remaining wells without the calibration curve had 75 μL 0.6% formic 
acid in HPLC-grade water added to them. Immediately prior to the extraction of the BChE 
protein, 10 μL of 2 mg/mL pepsin solution was added to every well of the digestion plate.
The sample plate, digestion plate, and three wash plates were loaded onto the KingFisher 
Flex to capture the bead bound BChE. The digestion plate was covered with adhesive foil, 
placed on the Eppendorf Thermomixer R for 30 minutes at 37°C with intermittent shaking at 
1,000 rpm for 10 seconds every minute.
Using the KingFisher Flex, the anti-BChE beads were removed from the digestion plate, 
leaving behind the pepsin digested sample. A 285 μL aliquot of acetonitrile and the digested 
samples were added to a protein precipitation plate. The protein precipitation plate was 
shaken for 1 minute at 1,000 rpm. The digested samples were filtered through the protein 
precipitation plate using a vacuum manifold, eluting the sample into the deep 96-well plate. 
The eluent was dried using a TurboVap-96 (Biotage) at 70°C under a nitrogen stream. The 
samples were reconstituted with 75 μL 0.6% formic acid in HPLC-grade water, transferred 
to a 96-well PCR plate, and heat sealed.
The BChE biomarker peptides were analyzed on an AB Sciex 6500 triple quadruple mass 
spectrometer interfaced with an Agilent 1290 Infinity series HPLC. Data was collected with 
Analyst 1.6 (AB Sciex) using Multiple Reaction Monitoring (MRM), with a dwell time of 
15 ms for each of the nine transitions, as summarized in Figure 2a. The TurboIonSpray 
source operated in positive ion mode and under the following parameters: curtain gas= 10 
psi; collision gas= 10 psi; ionspray voltage= 5500 V; temperature= 400°C; ion gas source 1= 
20 psi and ion gas source 2= 10 psi. The collision energy and declustering, entrance, and 
collision cell exit potentials were optimized for each transition and are reported in Figure 2a. 
The fragmentation patterns of these peptides have been previously reported [16]. The 
peptide extract (10 μL) was separated by reversed-phase chromatography using an Aquasil 
C18 HPLC. Mobile phases were 0.1% formic acid in HPLC-grade water (mobile phase A) 
and aqueous acetonitrile (mobile phase B). A segmented gradient was run over 5 minutes 
and at a flow rate of 75 μL/min as previously described [16]. The segmented gradient 
yielded elution times of 1.86 – 2.11 (± 0.2min) for all analytes. Extracted ion 
chromatograms were assessed on Analyst 1.6 for correct analyte peak shape, retention time 
and manually integrated when needed (Fig. 2b–c).
Validation/Characterization
QC characterization/validation was comprised of 20 analytical runs performed by three 
analysts (an analytical run contains one calibration curve in matrix blank and five QC 
materials) and 192 human samples. A maximum of two runs were prepared and analyzed per 
day over the span of five months. Linearity, precision and accuracy were determined and the 
limits of detection were calculated using the Taylor method [25]. Matrix effects were 
addressed by comparing non-matrix and matrix based calibrators. Ruggedness was assessed 
by altering the method’s parameters and measuring the deviations in accuracy.
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Results and Discussion
Linearity and Sensitivity
Following the completion of the 20 characterization runs, statistical analysis was conducted 
to validate the IMS method. Calibration curves were linear for all three analytes with a 
coefficient of determination value >0.99. The linear range was 4–250 ng/mL for unadducted 
BChE and 1–250 ng/mL for GB-BChE and VX-BChE. The limits of detection (LOD) and 
limits of quantitation (LOQ) were calculated using the Taylor method, in which 3 calibrators 
(low, mid and high) were analyzed for standard deviation (SD). The SD was plotted against 
the respective concentration and calculated as 3 times (LOD) or 10 times (LOQ) the y-
intercept [25]. The calculated LOD values for the analytes, BChE, GB-BChE and VX-BChE 
were 1.42, 0.79 and 0.43 ng/mL, respectively for the quantitation ions. The lowest calibrator 
for each analyte was higher than the calculated LOD. Precision was determined by 
calculating the mean percent relative standard deviation (%RSD) of the eight calibrators 
through the 20 analytical runs. The mean %RSD for the 8 calibrators were 8.1%, 6.1% and 
5.4%, corresponding to BChE, GB-BChE and VX-BChE native peptides (Table 1).
Peptide Stability and Recovery
Peptide temperature and freeze-thaw stability were evaluated by spiking the peptides into 
processed matrix blank. Both native and 13C9-isotopically labeled peptides were stable for at 
least 2 months at room temperature and greater than six months when stored at −70°C. 
Peptide calibrators suspended in 0.6% formic acid in HPLC-grade water were subjected to 
four freeze-thaw cycles from −70°C to 22°C and found to be stable. For both the 
temperature and the freeze-thaw stability cycles, the peptides were found to be within ± 10% 
of the theoretical.
Peptide recovery was measured by comparing the peak area of unprocessed calibrators to the 
peak area of processed calibrators. The unprocessed calibrators were added immediately 
before LC-MS/MS analysis (n=5) while the processed samples were added prior to pepsin 
digestion (n=5). Peptide recovery was 80± 14%, 74± 8%, and 75± 8% for BChE, GB-BChE 
and VX-BChE native peptides, respectively. To examine potential sources of peptide loss, 
peptide digestion and possible peptide adhesion to the wells was investigated. Ultimately the 
decrease in peptide recovery was not from the over- or under-digestion of the peptide. A 
slight decrease in peptide signal due to the adhesion of certain peptides to the wells was 
observed when compared to samples resuspended in low binding protein plates.
Quality Control Statistics
QC materials were evaluated according to amended Westgard rules [26, 27]. Analytical 
results were considered “out-of-control” if a QC control fell outside of the 3 SD confidence 
interval. The second parameter for QC exclusion occurred if two consecutive QC results fell 
outside of the 2 SD confidence interval. The mean calculated concentrations and %RSD for 
unadducted BChE, GB-BChE and VX-BChE QC materials are shown in Table 2.
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BChE Protein Recovery
Optimization efforts resulted in an increase in BChE protein recovery. Knaack et al. 
previously reported capturing 53.4% of the BChE protein using the anti-BChE beads [24]. 
By increasing the ratio of beads to serum by 3-fold, the optimized IMS-LC-MS/MS method 
captures ≥40% more BChE protein compared to the previous method (Table 3). BChE 
protein extraction efficiency was determined by analyzing FGES198AGAAS peptide levels 
from QCH BChE, QCH GB and QCH VX serum QC materials that were depleted three 
times with BChE Ab-conjugated beads. As a result, ≥88% of the BChE protein was 
extracted during the first incubation with the beads. Exhaustive BChE protein extraction 
occurred with three depletions.
IMS-LC-MS/MS Method Optimization
To improve robustness, several key parameters were tested and optimized. Native and 
labeled peptides were added prior to pepsin digestion instead of spiked at the end of the 
method in order to account for losses during sample preparation. This was the earliest point 
of addition as anti-BChE beads would not capture the peptide calibrators. Matrix effects 
were assessed by comparing matrix and solvent-based (i.e. 0.6% formic acid in HPLC-grade 
water) calibration curves. The slopes between the two matrices were greater than 5% 
different; therefore, the slopes were not equivalent and a matrix-based curve is required for 
accurate quantitation. Sample preparation time was decreased by adjusting the digestion 
conditions and peptide clean-up process. The BChE protein was fully digested into the nine 
amino acid peptide, FGES198AGAAS, within 30 minutes, reducing the digestion time from 
2 hours. The digestion reaction was quenched by adding acetonitrile and filtered through a 
protein precipitation plate. As a result of the digestion and filtration modifications, the 
sample preparation time reduced from 8 to 4 hours.
The reported method requires only 75 μL of filtered sample. By increasing BChE protein 
recovery, the sample volume was reduced 4-fold without decreasing sensitivity. The lower 
sample volume requirement allows for potential pediatric samples and limited sample 
volumes that would be expected in an OPNA chemical emergency. Due to the limitations of 
the previous method, results were reported as percent adducted/unadducted BChE. The 
current method allows for the direct reporting of quantitative values of unadducted BChE, 
GB-BChE and VX-BChE nine amino acid peptide.
During ruggedness testing several conditions were monitored including, digestion time and 
temperature, enzyme concentration, and sample concentration with nitrogen drying. 
Reducing digestion time to less than 30 minutes resulted in the under-digestion of BChE. 
Other actions that did not affect BChE were increasing the digestion times up to 2 hours, 
increasing pepsin concentration 4-fold, and varying the drying temperatures under nitrogen 
pressure between 37°C to 70°C.
BChE Protein Stability and Handling
Baseline BChE levels in the 192 matched plasma, serum and blood specimens were 
analyzed to compare results among the matrices. Establishing baseline BChE levels is 
essential since BChE is endogenous in >99.9% of the population [20]. Values outside 1 SD 
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of the average BChE concentration for healthy unexposed individuals could be “flagged” for 
potential OP exposure. A cut-off of 1 SD increases the number of samples that will have to 
be tested but avoids false negatives. Based on this premise, a high throughput prioritization 
method to profile ChE adducts was recently developed [28].
During the shipment of the convenience set samples, red blood cell lysis was indicated in the 
whole blood specimens by the discoloration of the harvested plasma samples. Despite lysis 
of the red blood cells, plasma and blood produced similar BChE results and therefore, can be 
used interchangeably. The BChE concentrations in the serum, plasma, and plasma harvested 
in-house from whole blood were 34.8 ± 7.8 ng/mL, 34.0 ± 9.2 ng/mL and 36.0 ± 7.7 ng/mL 
(mean concentration ± SD), respectively. As a result, these three matrices can be analyzed 
interchangeably for BChE quantification (Table 4).
Proper handling procedures and criteria for accepting or denying specimens were established 
by quantifying BChE levels under a variety of storage and sample handling conditions. 
Proper sample handling procedures have been previously established by the Clinical and 
Laboratory Standards Institute (CLSI) [29]. However, specimens received during an 
emergency may not always be acquired and/or stored under proper conditions prior to 
delivery. Blood, serum and plasma were collected from pooled convenience set samples. 
Pooled samples were aliquoted and immediately analyzed (t= 0 days) or stored at 37°C, 
22°C, 4°C, −20°C or −70°C. Triplicate plasma, serum and blood aliquots at each 
temperature were analyzed immediately or after 1, 7 or 14 days. The BChE protein in 
plasma, serum, and blood was found to be stable up to 2 weeks when stored between 37°C 
to − 70°C. When frozen, whole blood was severely lysed and required centrifugation 
through a 0.45 um filter prior to analysis.
Aged OP-adducted BChE
Despite these improvements, the reported method is unable to measure aged adducts. To 
address aged OP adducts, a simultaneous method to quantify the methylphosphonic acid 
(MeP) adduct to serine-198 on BChE was developed [30]. The MeP adduct is the product of 
aged V- and G- series OPNAs having a direct phosphorus-methyl bond. Although MeP is 
specific to OPCW Schedule 1 chemicals in general and not the exact OPNA of exposure, it 
is chemically stable and allows for the retrospective detection of aged OPNA adducts which 
contain the signature phosphorus-methyl bond. An alternate method to quantify OPNA 
adducts to tyrosine-411 on albumin following BChE depletion is currently under 
development in this laboratory.
Conclusion
In summary, an optimized method to confirm G- and V-series organophosphorus nerve agent 
exposure in human serum, plasma, and blood by quantifying butyrylcholinesterase 
biomarker peptides has been developed. The recent modifications have decreased sample 
volume requirements significantly without influencing LC-MS/MS method or limits of 
detection. In addition, the reported method reduces sample processing time by half and has 
endured ruggedness testing.
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The stability of BChE and baseline BChE levels among various matrices has been 
demonstrated. Criteria for the acceptance of clinical samples for this method exceed the 
recommendations provided by CLSI and include considerations such as improper sample 
handling and storage. Plasma, serum, and plasma harvested from whole blood can be 
analyzed interchangeably using this method. Specimen stability experiments showed that 
plasma, serum, and blood samples stored at 37°C or colder for two weeks are stable, but 
whole blood samples need to be filtered if frozen.
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Abbreviations
OPNA organophosphorus nerve agents
BChE butyrylcholinesterase
IMS immunomagnetic separation
LC-MS/MS liquid chromatography tandem mass spectrometry
OP organophosphorus
ChE cholinesterase
GB sarin
AChE acetylcholinesterase
TNO The Netherlands Organisation for Applied Scientific Research
Ab antibody
QC quality control
F phenylalanine
G glycine
E glutamic acid
S serine
A alanine
LRL lowest reportable limit
QCH quality control high
QCL quality control low
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MRM Multiple Reaction Monitoring
LOD limit of detection
LOQ limit of quantitation
RSD relative standard deviation
CLSI Clinical and Laboratory Standards Institute
MeP methylphosphonic acid
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Fig. 1. 
IMS Coupled with LC-MS/MS Methodology
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Fig. 2. 
HPLC-MS/MS chromatograms and transitions. (A) Multiple Reaction Monitoring (MRM) 
Transitions for HPLC-MS/MS analysis of the analytes. An overlay of the reconstructed 
MRM chromatograms for (B) QC material and (C) native and isotopically labeled synthetic 
peptides. Q= Quantitation ion; C= confirmation ion; ISTD; Internal standard; DP= 
declustering potential; EP= entrance potential; CE= collision energy; CxP= collision cell 
exit potential
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Table 1
Calculated Limits and Precision of Calibrators (N=20).
Analyte LOD (ng/mL) LOQ (ng/mL) Mean RSD (%)
BChE 1.42 4.73 8.13
BChE_C 1.34 4.47 5.74
GB-BChE 0.79 2.63 6.13
GB-BChE_C 0.69 2.30 6.03
VX-BChE 0.43 1.43 5.44
VX-BChE_C 0.39 1.30 5.80
BChE= quantitation ion for BChE analyte; BChE_C= confirmation ion for BChE analyte
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Table 2
Interday Precision of QC Materials (N=20) Over 5 Months.
Quality Control Serum Calculated Conc. (± SD) (ng/mL) RSD (%)
QCH BChE 39.44 (± 3.44) 8.60
QCL BChE 21.46 (±2.14) 9.70
QCH GB 40.92 (±3.15) 7.77
QCL GB 10.43 (±1.01) 9.18
QCH VX 41.16 (±3.13) 8.71
QCL VX 8.38 (± 1.55) 18.88
QCL= Quality Control Low, QCH= Quality Control High
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Table 3
Optimized IMS Protein Recovery of BChE from Serum
Depletion Number
Previous Method (% Total) Current Method (% Total)
QCH BChE QCH BChE QCH GB QCH VX
1 53.4 88.2 92.2 95.4
2 38.0 6.8 6.5 4.6
3 8.6 5.0 1.3 0.0
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Table 4
Convenience set from 192 matched-set plasma, serum and blood samples.
Matrix BChE Conc. (± SD) (ng/mL) BChE Range(ng/mL) %RSD
Plasma 34.8 (± 7.8) 16.3–58.3 22.41
Serum 34.0 (± 9.2) 13.8–57.7 27.06
Blood* 36.0 (±7.7) 16.5–57.7 21.39
*Plasma was collected from blood in-house immediately after arrival
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